Publications by authors named "Araceli Mezcua"
Article Synopsis
- * 127 patients were monitored, and findings revealed that 24% of them developed ADA, with age playing a significant role in this relationship.
- * In individuals over 55 years old, higher BAFF levels (≥ 1034 pg/mL) were strongly predictive of ADA development, suggesting that BAFF concentration may help to anticipate immunogenicity in older patients undergoing TNFi therapy.
Biosimilars are replacing originator compounds due to their similar effectiveness, safety and pharmacokinetics. Our objective was to compare the differences in pharmacokinetics and clinical outcomes between the originator infliximab (Ifx) and the biosimilar CT-P13 in a patient cohort with inflammatory bowel disease (IBD). Our cohort study included 86 patients from a historical and a prospective cohort from the start of infliximab treatment to 22 weeks later.
View Article and Find Full Text PDFObjectives: To investigate the association between serum golimumab (GLM) trough levels, clinical disease activity and treatment response during the first year of therapy in patients with axial spondyloarthritis (axSpA), as well as determining an optimal concentration range of GLM in axSpA.
Methods: This was an observational prospective study including 49 patients with axSpA monitored during 52 weeks (W52). Serum GLM trough levels were measured by capture ELISA and antidrug antibodies by bridging ELISA at baseline, W24 and W52.